Equity Overview
Price & Market Data
Price: $1.08
Daily Change: +$0.01 / 0.93%
Range: $1.05 - $1.08
Market Cap: $90,135,176
Volume: 80,596
Performance Metrics
1 Week: 6.93%
1 Month: 8.46%
3 Months: -26.03%
6 Months: -42.25%
1 Year: -41.30%
YTD: -15.62%
Company Details
Employees: 22
Sector: Health technology
Industry: Biotechnology
Country: Canada
Details
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.